|
PRKAB2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62470037423645E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.99760216648792E-15 |
| Normal-vs-Stage2 |
3.51569999779144E-08 |
| Normal-vs-Stage3 |
1.7670309659934E-12 |
| Normal-vs-Stage4 |
3.28570000096562E-08 |
| Stage1-vs-Stage2 |
7.951800E-01 |
| Stage1-vs-Stage3 |
9.166800E-01 |
| Stage1-vs-Stage4 |
6.139200E-01 |
| Stage2-vs-Stage3 |
7.498400E-01 |
| Stage2-vs-Stage4 |
8.504600E-01 |
| Stage3-vs-Stage4 |
5.795200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.66133814775094E-16 |
| Normal-vs-AfricanAmerican |
1.820350E-04 |
| Normal-vs-Asian |
3.09399994513626E-09 |
| Caucasian-vs-AfricanAmerican |
2.833200E-01 |
| Caucasian-vs-Asian |
8.579000E-01 |
| AfricanAmerican-vs-Asian |
2.749200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.34599997814178E-09 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
3.985900E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.26818563930919E-12 |
| Normal-vs-Age(41-60Yrs) |
2.1094237467878E-15 |
| Normal-vs-Age(61-80Yrs) |
5.26770005393473E-09 |
| Normal-vs-Age(81-100Yrs) |
1.315100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.291800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.838030E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.196600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.013620E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.695000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.315000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.876300E-02 |
| Classical-VS-Follicular |
6.522400E-01 |
| Classical-VS-Other |
6.495200E-01 |
| Classical-VS-Normal |
8.65389981896669E-10 |
| Tall-VS-Follicular |
2.265000E-01 |
| Tall-VS-Other |
3.967800E-01 |
| Tall-VS-Normal |
2.10229944563878E-10 |
| Follicular-VS-Other |
5.939200E-01 |
| Follicular-VS-Normal |
3.89600018912972E-10 |
| Other-VS-Normal |
5.761600E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.85327317328665E-14 |
| Normal-vs-N1 |
4.3489989387524E-11 |
| N0-vs-N1 |
4.258600E-01 |
|
|
